The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Oral Drug Product Development of Small Molecules
Read More
webinar
Ask Me Anything Series – CMC and Regulatory Alignment: Lessons from the Front Lines
Read More
white-paper
The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China
Read More
post
Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in
Read More
Let's move from science to success.
Let’s Talk